Literature DB >> 20959536

Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes.

Manish Suneja1, Daryl J Murry, John B Stokes, Victoria S Lim.   

Abstract

To assess whether endocrine dysfunction may cause derangement in energy homeostasis in patients undergoing hemodialysis (HD), we profiled hormones, during a 3-day period, from the adipose tissue and the gut and the nervous system around the circadian clock in 10 otherwise healthy HD patients and 8 normal controls. The protocol included a 40-h fast. We also measured energy-protein intake and output and assessed appetite and body composition. We found many hormonal abnormalities in HD patients: 1) leptin levels were elevated, due, in part, to increased production, and nocturnal surge in response to daytime feeding, exaggerated. 2) Peptide YY (PYY), an anorexigenic gut hormone, was markedly elevated and displayed an augmented response to feeding. 3) Acylated ghrelin, an orexigenic gut hormone, was lower and did not exhibit the premeal spike as observed in the controls. 4) neuropeptide Y (NPY), a potent orexigenic peptide, was markedly elevated and did not display any circadian variation. 5) Norepinephrine, marginally elevated, did not exhibit the normal nocturnal dip. By contrast, α-melanocyte-stimulating hormone and glucagon-like peptide-1 were not different between the two groups. Despite these hormonal abnormalities, HD patients maintained a good appetite and had normal body lean and fat mass, and there was no evidence of increased energy expenditure or protein catabolism. We explain the hormonal abnormalities as well as the absence of anorexia on suppression of parasympathetic activity (vagus nerve dysfunction), a phenomenon well documented in dialysis patients. Unexpectedly, we noted that the combination of high leptin, PYY, and NPY with suppressed ghrelin may increase arterial blood pressure, impair vasodilatation, and induce cardiac hypertrophy, and thus could predispose to adverse cardiovascular events that are the major causes of morbidity and mortality in the HD population. This is the first report attempting to link hormonal abnormalities associated with energy homeostasis to adverse cardiovascular outcome in the HD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959536      PMCID: PMC3023209          DOI: 10.1152/ajpendo.00438.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  70 in total

1.  What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?

Authors:  J Bergström; B Lindholm; E Lacson; W Owen; E G Lowrie; R J Glassock; T A Ikizler; F J Wessels; L L Moldawer; C Wanner; J Zimmermann
Journal:  Semin Dial       Date:  2000 May-Jun       Impact factor: 3.455

2.  Effect of dialysis and renal transplantation on autonomic dysfunction in chronic renal failure.

Authors:  A Agarwal; I S Anand; V Sakhuja; K S Chugh
Journal:  Kidney Int       Date:  1991-09       Impact factor: 10.612

Review 3.  Clinical applications of visual analogue scales: a critical review.

Authors:  H M McCormack; D J Horne; S Sheather
Journal:  Psychol Med       Date:  1988-11       Impact factor: 7.723

4.  National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure.

Authors:  J D Kopple
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

5.  Role of the central melanocortin system in cachexia.

Authors:  D L Marks; N Ling; R D Cone
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Neural regulation of peptide YY secretion.

Authors:  T Zhang; T Uchida; G Gomez; F Lluis; J C Thompson; G H Greeley
Journal:  Regul Pept       Date:  1993-11-03

Review 8.  Neuropeptide Y and cardiovascular regulation.

Authors:  T Pedrazzini; H R Brunner; B Waeber
Journal:  Curr Opin Nephrol Hypertens       Date:  1993-01       Impact factor: 2.894

9.  Sympathetic overactivity in patients with chronic renal failure.

Authors:  R L Converse; T N Jacobsen; R D Toto; C M Jost; F Cosentino; F Fouad-Tarazi; R G Victor
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

10.  Effects of peptide YY on the human cardiovascular system: reversal of responses to vasoactive intestinal peptide.

Authors:  R J Playford; M A Benito-Orfila; P Nihoyannopoulos; K A Nandha; J Cockcroft; S Todd; M A Ghatei; J Domin; S R Bloom; J Calam
Journal:  Am J Physiol       Date:  1992-10
View more
  8 in total

1.  Correlates of leptin in children with chronic kidney disease.

Authors:  Edward Nehus; Susan Furth; Bradley Warady; Mark Mitsnefes
Journal:  J Pediatr       Date:  2014-07-25       Impact factor: 4.406

2.  Characterization of the diurnal rhythm of peptide YY and its association with energy balance parameters in normal-weight premenopausal women.

Authors:  Brenna R Hill; Mary Jane De Souza; Nancy I Williams
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-24       Impact factor: 4.310

3.  Association of plasma des-acyl ghrelin levels with CKD.

Authors:  Rohit K Gupta; Tamil Kuppusamy; James T Patrie; Bruce Gaylinn; Jianhua Liu; Michael O Thorner; Warren K Bolton
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-06       Impact factor: 8.237

Review 4.  Ghrelin and leptin pathophysiology in chronic kidney disease.

Authors:  Sujana S Gunta; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2012-12-11       Impact factor: 3.714

Review 5.  Pathophysiology of Non Alcoholic Fatty Liver Disease.

Authors:  Salvatore Petta; Amalia Gastaldelli; Eleni Rebelos; Elisabetta Bugianesi; Piergiorgio Messa; Luca Miele; Gianluca Svegliati-Baroni; Luca Valenti; Ferruccio Bonino
Journal:  Int J Mol Sci       Date:  2016-12-11       Impact factor: 5.923

6.  Interaction between acyl-ghrelin and BMI predicts clinical outcomes in hemodialysis patients.

Authors:  Ilia Beberashvili; Inna Sinuani; Ada Azar; Gregory Shapiro; Leonid Feldman; Keren Doenyas-Barak; Kobi Stav; Shai Efrati
Journal:  BMC Nephrol       Date:  2017-01-18       Impact factor: 2.388

Review 7.  Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Authors:  Raymond Vanholder; Anneleen Pletinck; Eva Schepers; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

Review 8.  Metabolic syndrome in children with chronic kidney disease and after renal transplantation.

Authors:  Mieczysław Litwin; Anna Niemirska
Journal:  Pediatr Nephrol       Date:  2013-06-13       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.